Natural Course and Molecular Basis of Alpha 1- Antitrypsin Deficiency-associated Liver Disease.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
* To define the course of AATD-associated liver disease. * To use the obtained samples for biomedical research which includes:
1. Search for serum-based disease biomarkers and the associated molecular pathways. 2. Multi-omic spatial analysis of human AATD-LD.
Eligibility criteria
Qualifiers
Adult patients (≥18 years) with genetically confirmed alpha-1 antitrypsin deficiency (Pi*ZZ genotype).
Availability of longitudinal clinical follow-up data (minimum 5 years) within the AATD consortium.
At least one documented liver assessment including liver stiffness measurement (LSM) and serum-based fibrosis markers.
Availability of stored serum samples for proteomic analysis.
Disqualifiers
Presence of other chronic liver diseases (e.g., viral hepatitis, autoimmune hepatitis) that may confound fibrosis assessment.
History of liver transplantation prior to study inclusion.
Incomplete clinical, laboratory, or follow-up data.
Poor-quality or insufficient biological samples for proteomic or molecular analyses.
Trial design
Treatments tested in this trial
- Multi-omic spatial analysis
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov